The company said it found and validated CGEN-671, the potential target for cancer treatments, potentially providing information that could be employed to better tailor treatments to target a wide range of cancers. The goal is the target Epithelial tumors, or carcinomas, which account for roughly 85 percent of all cancers.
Stocks of Compugen soared up $1.39, or 24 percent, to $5.47.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
Sign up for a free one-year subscription to EQUITIES Magazine
